Longevity & AgingAlzheimer's Blood Tests Expand to Latin America and Caribbean
C2N Diagnostics and SouthGenetics have partnered to expand Alzheimer's blood-based biomarker testing across Latin America and the Caribbean, starting in nine countries including Mexico, Colombia, and Argentina. The Precivity blood test portfolio detects biological signals in the bloodstream linked to Alzheimer's pathology, offering a less expensive and more accessible alternative to specialized brain imaging. This matters because aging populations across the region face growing dementia burdens while access to specialist diagnostics remains limited. The tests are not standalone diagnostic tools but provide additional clinical information to guide physicians. The expansion reflects a broader shift toward earlier Alzheimer's detection, which is increasingly important as new therapies emerge that work best when initiated early in disease progression.
